The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year


About Translational Research in Oncology

Translational Research in Oncology (TRIO) is a not-for-profit academic clinical research organization that is dedicated to advancing translational cancer research by bringing forward therapeutic concepts into the clinical trial setting.

Translational Research in Oncology Headquarter Location

9925 109 St NW Suite 1100

Edmonton, Alberta, AB T5K 2J8,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Translational Research in Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Translational Research in Oncology is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Translational Research in Oncology News

Translational Research in Oncology (TRIO) Appoints Board Member

May 20, 2021

Translational Research in Oncology Edmonton, Alberta, CANADA EDMONTON, Alberta, May 20, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced the appointment of Prof. Seock-Ah Im to the Company’s Board of Directors, effective March 15, 2021. Based in South Korea, Prof. Seock-Ah Im brings significant experience in key areas including translational research and clinical trial development. The appointment of Prof. Seock-Ah Im to TRIO's Board builds upon a successful working history with the Korean Cancer Study Group (KCSG). Prof. Seock-Ah Im joins current board members Dr. Peter Fasching, Dr. John Glaspy, Dr. Hari Kumar, Dr. Miguel Martin, Dr. Dennis Slamon and Fran Visco. “On behalf of the Board of Directors, it is a pleasure to welcome Prof. Seock-Ah Im to the Board,” said Dr. Dennis Slamon, TRIO’s Executive Director. “Her collective experience, in and out of the laboratory, will complement our current Board of Directors’ skills and experiences. We look forward to working with Prof. Seock-Ah Im and leveraging her unique expertise.” About Dr. Seock-Ah Im Dr. Seock-Ah Im currently holds the position of Director of Cancer Research Institute at Seoul National University. Her clinical work is focused on the development of tailored therapy through translational research and clinical trials to maximize clinical utility. In addition, she serves as Chair to both the International Cooperation Committee of Korean Cancer Study Group (KCSG) and the Scientific Committee of Korean Society of Medical Oncology (KSMO). About TRIO TRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting. With international offices in Edmonton (Canada), Paris (France), Montevideo (Uruguay), TRIO’s global reach is expansive. Our goal as an academic clinical research organization is to find the shortest path to saving lives. Additional information on TRIO can be found by visiting . Interested parties may also follow TRIO on Twitter ( ). TRIO Media Inquiries:

Translational Research in Oncology Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Translational Research in Oncology Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.